Pharmacogenetic testing of CYP2D6 in patients with aripiprazole-related extrapyramidal symptoms: a case––control study. (July 2008)

• Record Type: Journal Article
• Authors: Subuh Surja, Anton A; Reynolds, Kristen K; Linder, Mark W; El-Mallakh, Rif S
• Is Part Of: Personalized medicine. Volume 5:Number 4(2008)
• Page Start: 361
• Page End: 365
• Publication Date: 2008-07
• Subjects: adverse drug reaction -- aripiprazole -- bipolar disorder -- CYP2D6 -- extrapyramidal symptoms -- gene polymorphisms; Pharmacogenomics -- Periodicals; Pharmacogenetics -- Periodicals; 615.19
• DOI: 10.2217/17410541.5.4.361
• Languages: English
• ISSNs: 1741-0541

Abstract

Aripiprazole is primarily metabolized by the polymorphic CYP2D6. We genotyped four children (aged 6––15 years) who had developed extrapyramidal symptoms within 1 week of aripiprazole initiation or dose titration, and four matched children without extrapyramidal symptoms. All of the four children who developed extrapyramidal symptoms with aripiprazole had a dysfunctional CYP2D6 enzyme, based on genotype, and were categorized as either intermediate metabolizers (n = 2) or poor metabolizers (n = 2). By contrast, only two children from the control group had either of these phenotypes, and both were intermediate metabolizers. Children with CYP2D6 abnormalities may be at higher risk of aripiprazole-induced adverse drug reactions.